Novavax Provides Phase 3 COVID-19 Vaccine Clinical Development Update
Go back to Novavax Provides Phase 3 COVID-19 Vaccine Clinical Development Update| Novavax, Inc. (NASDAQ: NVAX) | Delayed: 7.95 +0.21 (2.71%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $7.74 | 52 Week High | $9.23 | |||
| Open | $7.75 | 52 Week Low | $1.16 | |||
| Day High | $8.09 | P/E | N/A | |||
| Day Low | $7.60 | EPS | $-0.30 | |||
| Volume | 5,703,058 | |||||
